Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Dactolisib (BEZ235, NVP-BEZ235) Chemical Structure

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

11 Customer Reviews

  • Level of phospho-proteins in RTK and PI3K–Akt–mTOR pathways in treated tumours, detected with western blot.

    Nature, 2017, 728-732. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

    A, ANOVA of IC50 values of the dual PI3K/mTOR inhibitor NVP-BEZ235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and Braf wild-type cells. B, decreases in pAkt and pP70S6K in a dose and time-dependent fashion in 2 melanoma cell lines treated with NVP-BEZ235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependent fashion. C, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ235 at different concentrations. NVPBEZ235 was effective in inhibiting colony formation at low nanomolar concentrations.

    Clin Cancer Res 2010 16, 6029-6039. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

  • Relative kinase activities of p110α mutants and the inhibitory effect of PI3K inhibitors against hotspot mutants of p110α. A, recombinant FLAG-tagged PI3K p110α/p85α protein complex produced in 293T cells was immunoprecipitated , and the immunoprecipitates were used for the quantitative PI3K-HTRF assay (32).

    B, effect of three PI3K inhibitors (ZSTK474, LY294002, and NVP-BEZ235) on the enzymatic activity of two hotspot mutants (E545K and H1047R) p110α compared with the wild-type. No striking difference was observed in the IC50 concentrations of these inhibitors between wild-type and mutant p110α.
     

     

    Cancer Res 2010 70, 4982-4994. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

    ZSTK474 and GDC-0941 selectively inhibit class I PI3K over mTOR. (A) Inhibition profiles of the selected five PI3K inhibitors for mTOR. Data shown are mean±SD (n = 3), representative of 2 or 3 independent experiments. (B) IC50 values of the PI3K inhibitors for mTOR. (C) Selectivity of each PI3K inhibitor for PI3Ka over mTOR. The selectivity index is expressed as the ratio of the IC50 value for mTOR over that for PI3Ka. The IC50 values of ZSTK474, NVP-BEZ235 and LY294002 for PI3Ka are 0.016, 0.007 and 0.6 μM, respectively, as reported previously by us.

     

     

    Eur J Cancer 2010 46, 1111-1121. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

  • Three-dimensional responses of MCF7/IGF-1R cells to TAM (1 μM), E2 and IGF-1. Compared to parental MCF7 cells (a), MCF7/IGF-1R cells (b) in three-dimensional (3D) culture formed bigger acini in response to IGF-1 stimulation and displayed significant TAM resistance when treated with TAM (1 μM) + E2 + IGF-1, which was removable by kinase inhibitors BMS-536924, U0126 and BEZ235 (c). Cells (10,000/well) were seeded in 96-well plates. Acini were formed on 100% Matrigel and cultured for 14 days in starving medium containing 2% Matrigel and 5% charcoal/dextran-stripped fetal bovine serum with the treatments as indicated. Concentrations used: TAM (1 μM), E2 (1 nM) and IGF-1 (100 ng/mL). Confocal image original magnification, × 20. Red, rhodamine phalloidin (actin). Blue, Hoechst blue stain. Results are representative of two individual experiments.

    Breast Cancer Res 2011 13, R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

    TAM (10 nM) agonistic behavior in MCF7/IGF-1R cells is not inhibited by phosphatidylinositol 3-kinase/Akt inhibitor BEZ235. (a) Inhibitory effects of kinase inhibitors BMS-536924, U0126 and BEZ235 on agonistic effect of TAM (10 nM) in the presence of IGF-1 (100 ng/mL). **P < 0.01. (b) Inhibitory effects of phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor BEZ235 at various dose ranges on IGF-1R signaling. (c) Agonistic behavior of TAM (10 nM) in response to BEZ235 kinase inhibitor. (-), no BEZ235. Results are representative of three independent experiments. Data are expressed as means ± SD.

    Breast Cancer Res 2011 13:R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

    The effects of LY294002, rapamycin and NVP-BEZ235 on activation of PI3K-Akt-mTOR pathway in hepatocytes. (a) The mRNA expression (PI3K, Akt, mTOR, raptor) by Real-Time PCR, (b) protein expression (PI3K, Akt, mTOR, S6K) by ELISA kits; (c) protein expression of S6K and P-S6K by western blotting. The different letters indicated significant differences (P <0.05). LY = LY294002; rapa = rapamycin; NVP = NVP-BEZ235.

    Animal, 2016, 10(8):1319-27. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

  •  After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute  stimulation of 100ng/ml EGF.

     

     

     

    Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

    After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute  stimulation of 100ng/ml EGF.

     

     

    Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

  •  

    FIG. 4. Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts. The bar graph shows the quantification of the immunoblots (mean±SD). PLA2G4A, Ethanolamine kinase 1 and 2 (ETNK1/2), Choline kinase alpha/beta (ChoKA/B), and β-actin protein expression were examined by immunoblotting of tissue samples after MRS experiments [control group (n= 5) and BEZ235-treated group (n=7)]. This demonstrated a higher expression of PLA2G4A protein ( P=0.005), but no changes in ETNK1 and ChoKA/B in samples from basal-like xenografts treated with BEZ235.

    Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.
Targets
p110α [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 mTOR (p70S6K) [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 ATR [8]
(3T3TopBP1-ER cells)
4 nM 5 nM 6 nM 7 nM 21 nM
In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. [1] BEZ235 is an mTORC1/2 catalytic inhibitor. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Trypanosoma brucei brucei MWrBcpRqdWmlcn;ibYFtKEG|c3H5 MkjpNVghcA>? M1\F[mROW09? M4O1PWFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1? M3rzcVI1QDB3OUS2
MCF7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHnOIIxNjBzLUGwNEDPxE1? MUO0PEBp NY\EW2xSTE2VTx?= NEnNcIpKSzVyPUCuO|Mh|ryP M4DIWFI{QDdzOUC0
HCT116 NUHwOnBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmNE4xOS1zMECg{txO Mle1OFghcA>? M1jQOGROW09? NX[5NVdtUUN3ME2xMlE3KM7:TR?= Mn\uNlM5PzF7MES=
U87MG NUPW[XI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTRNE4xOS1zMECg{txO MmexOFghcA>? NGTTS5JFVVOR M3O1[mlEPTB;MT6zNkDPxE1? M1LkV|I{QDdzOUC0
HBC4 NVjafHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[wMlAyNTFyMDFOwG0> MUG0PEBp MnviUI9oKEeLNUC9MVgvPjFiTR?= MX:yNlM{PjJ2Nh?=
BSY1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv0dY8zOC5yMT2xNFAh|ryP NG\hNFI1QCCq MYfMc4chT0l3ME2tPE41QCCP M{[4W|IzOzN4MkS2
HBC5 NXHJSVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjpXnMxNjBzLUGwNEDPxE1? NYDqcYprPDhiaB?= NIT3emlNd2diR1m1NF0uPy56NzDN MlrzNlI{OzZ{NE[=
MCF7 NHX6RZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jkN|AvODFvMUCwJO69VQ>? NYXQWZFQPDhiaB?= M2jtV2xw\yCJSUWwQU05NjF4IF2= NX;nc21wOjJ|M{[yOFY>
MDA-MB-231 NGntVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3vNE4xOS1zMECg{txO M1X6bVQ5KGh? MV3Mc4chT0l3ME2tPE4xQSCP NVq0emkxOjJ|M{[yOFY>
U251 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{naZVAvODFvMUCwJO69VQ>? NX75dlBwPDhiaB?= MWHMc4chT0l3ME2tO{43PiCP MUSyNlM{PjJ2Nh?=
SF268 M{Sxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG5S3YxNjBzLUGwNEDPxE1? Mm\4OFghcA>? MXvMc4chT0l3ME2tO{46OiCP MkTTNlI{OzZ{NE[=
SF295 NWfYWVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTqOmpoOC5yMT2xNFAh|ryP NFG0c|k1QCCq NX3R[Iw3VG:pIFfJOVA:NThwM{GgUS=> M4fZNFIzOzN4MkS2
SF539 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzrNE4xOS1zMECg{txO MXm0PEBp MY\Mc4chT0l3ME2tPE42QSCP Mn;XNlI{OzZ{NE[=
SNB75 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\FfoYxNjBzLUGwNEDPxE1? MXe0PEBp NYnzNm1qVG:pIFfJOVA:NThwNUigUS=> MYOyNlM{PjJ2Nh?=
SNB78 M2DmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv6blAxNjBzLUGwNEDPxE1? MXK0PEBp M3zJb2xw\yCJSUWwQU05NjZ3IF2= M{mx[FIzOzN4MkS2
HCC2998 M1PxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;VWnNNOC5yMT2xNFAh|ryP MXW0PEBp MXnMc4chT0l3ME2tPE4xPSCP MV2yNlM{PjJ2Nh?=
KM12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXQSlAxNjBzLUGwNEDPxE1? MnvNOFghcA>? NVP2SHlrVG:pIFfJOVA:NTdwNUSgUS=> M2ftO|IzOzN4MkS2
HT-29 M1K4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnFNE4xOS1zMECg{txO NYrrXWtxPDhiaB?= NHH6TVNNd2diR1m1NF0uPy55NTDN MXSyNlM{PjJ2Nh?=
HCT15 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LLTFAvODFvMUCwJO69VQ>? MUO0PEBp NGTkb3lNd2diR1m1NF0uQC5yMzDN M2fVRVIzOzN4MkS2
HCT116 NHPSWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYiwMlAyNTFyMDFOwG0> NX;DNmhoPDhiaB?= M3TIfWxw\yCJSUWwQU04NjZzIF2= NILPc5UzOjN|NkK0Oi=>
NCI-H23 M2\TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlAyNTFyMDFOwG0> MnXZOFghcA>? MVfMc4chT0l3ME2tO{43PCCP NGG2NFgzOjN|NkK0Oi=>
NCI-H226 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\jNE4xOS1zMECg{txO MoDROFghcA>? MXLMc4chT0l3ME2tPE41PCCP NXe3VG5xOjJ|M{[yOFY>
NCI-H522 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqwMlAyNTFyMDFOwG0> NIjTTWw1QCCq MkHOUI9oKEeLNUC9MVgvPDViTR?= MWqyNlM{PjJ2Nh?=
NCI-H438 M2P0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMlAyNTFyMDFOwG0> NY\6SVB6PDhiaB?= Ml7rUI9oKEeLNUC9MVgvOTFiTR?= NITVV2ozOjN|NkK0Oi=>
A549 M3f3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jnWFAvODFvMUCwJO69VQ>? NEHUeIg1QCCq NFizNnRNd2diR1m1NF0uQC5yNzDN MUKyNlM{PjJ2Nh?=
DMS273 M2jSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfDNE4xOS1zMECg{txO NIHVWYM1QCCq NXrZVGs5VG:pIFfJOVA:NTdwOECgUS=> MlvPNlI{OzZ{NE[=
DMS114 NHHiTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPlZnkxNjBzLUGwNEDPxE1? NFrmRnk1QCCq M{K0Smxw\yCJSUWwQU05NjN7IF2= MWmyNlM{PjJ2Nh?=
LOXIMVI M2X1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXywMlAyNTFyMDFOwG0> MYq0PEBp MVrMc4chT0l3ME2tPE43PiCP M4W0ZlIzOzN4MkS2
OVCAR3 NY\2clVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nWTVAvODFvMUCwJO69VQ>? NInrOpI1QCCq NGPB[VRNd2diR1m1NF0uQC5zNzDN MViyNlM{PjJ2Nh?=
OVCAR4 NV7Lb2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PQbFAvODFvMUCwJO69VQ>? NHT6fms1QCCq MmrDUI9oKEeLNUC9MVgvPThiTR?= M37VOlIzOzN4MkS2
OVCAR5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHR[poxNjBzLUGwNEDPxE1? MUC0PEBp M4K3S2xw\yCJSUWwQU04NjV5IF2= MW[yNlM{PjJ2Nh?=
OVCAR8 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7mNE4xOS1zMECg{txO M37hclQ5KGh? MWPMc4chT0l3ME2tO{45PCCP MoTtNlI{OzZ{NE[=
SKOV3 M2npcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC0VoNEOC5yMT2xNFAh|ryP MoLEOFghcA>? MVXMc4chT0l3ME2tPE41OSCP MYqyNlM{PjJ2Nh?=
RXF631L NGfRWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mfHhlOC5yMT2xNFAh|ryP M1jpdVQ5KGh? MnTaUI9oKEeLNUC9MVgvOjFiTR?= MnXmNlI{OzZ{NE[=
ACHN NHvpWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlAyNTFyMDFOwG0> NGD0[Yg1QCCq MWPMc4chT0l3ME2tO{46PSCP MUGyNlM{PjJ2Nh?=
St-4 NW\EcVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fwOlAvODFvMUCwJO69VQ>? NX7CfHBOPDhiaB?= Ml:0UI9oKEeLNUC9MVcvPDdiTR?= NVn1NHF6OjJ|M{[yOFY>
MKN1 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH22clMxNjBzLUGwNEDPxE1? M2DCRlQ5KGh? MVzMc4chT0l3ME2tPE41OSCP NHLXfo0zOjN|NkK0Oi=>
MKN7 NH70Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOwMlAyNTFyMDFOwG0> M4jQNlQ5KGh? NIKxPGZNd2diR1m1NF0uPy54ODDN NFTCb3czOjN|NkK0Oi=>
MKN28 NWDkUXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvUTVcxNjBzLUGwNEDPxE1? NWDu[oxGPDhiaB?= M37vXWxw\yCJSUWwQU04NjB5IF2= NVrFdGp3OjJ|M{[yOFY>
MKN45 NFPjWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPb4FbOC5yMT2xNFAh|ryP Mkf2OFghcA>? NVzuZlR6VG:pIFfJOVA:NThwM{SgUS=> NHn4VoUzOjN|NkK0Oi=>
MKN74 NWjUPIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TzVVAvODFvMUCwJO69VQ>? MYW0PEBp Mn;QUI9oKEeLNUC9MVcvPDJiTR?= M3HXOFIzOzN4MkS2
DU145 NGrTcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\rPVAvODFvMUCwJO69VQ>? M3rBSVQ5KGh? MlHOUI9oKEeLNUC9MVgvOTZiTR?= NXu1fXM3OjJ|M{[yOFY>
PC3 NVLqSWNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLyN4lHOC5yMT2xNFAh|ryP NVXY[IdUPDhiaB?= MX\Mc4chT0l3ME2tPE43PiCP Ml3oNlI{OzZ{NE[=
Trypanosoma brucei brucei NIXJS3ZHfW6ldHnvckBCe3OjeR?= NIXRS3czODBibl2= MnvmNVIhcA>? NV72Z2Y2TE2VTx?= MoDsSIVkemWjc3WgbY4heGixc4Doc5Rq\HmuIHnuc5NqfG:uIIDoc5NxcGG2ZTDs[ZZmdA>? MXGyOFgxPTl2Nh?=
Trypanosoma brucei brucei MkXBSpVv[3Srb36gRZN{[Xl? MWmxPEBp NIXaXYtFVVOR M{HBd2lvcGmkaYTpc44hd2ZicnXj[ZB1d3JvbXXkbYF1\WRiZX7kc4N6fG:|aYOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5idILhcpNn\XK{aX6geZB1[Wun MlXsNlQ5ODV7NE[=
Trypanosoma brucei brucei MknDSpVv[3Srb36gRZN{[Xl? MWqyNFAhdk1? M1H6SVEzKGh? MXLEUXNQ Mn3PSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw> NGTZZokzPDhyNUm0Oi=>
Trypanosoma brucei brucei M3\OVGZ2dmO2aX;uJGF{e2G7 M1jPNFIxOCCwTR?= MWmxNkBp Ml3BSG1UVw>? NVfzXZpJTW[oZXP0JI9vKHCqb4PwbIF1cWS7bHPoc4xqdmVibHX2[Yw> NF7QUmwzPDhyNUm0Oi=>
UM-UC-3 NY\6Tlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNzNTDwUS=> NHPOVIlUSU6JRWK=
SBC-1 M3LMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTsUnRJUUN3ME23OFIheE1? M3SyW3NCVkeHUh?=
MKN1 NI\0c|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rPN2lEPTB;Mj64JI5O NIrPemtUSU6JRWK=
NCI-H720 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD1|LkW3JI5O MVTTRW5ITVJ?
BFTC-909 M3vUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ZR5k5UUN3ME2zMlcyKG6P NELoWHZUSU6JRWK=
BPH-1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwN{[gcm0> M1;4cHNCVkeHUh?=
PC-3 NH;nO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwMEmgcm0> MVTTRW5ITVJ?
AN3-CA Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3TWM2OD13LkW2JI5O MnrOV2FPT0WU
HN NWPPU|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITabnVKSzVyPUWuPVYhdk1? NULURmRrW0GQR1XS
HCC2218 NFf2NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3W2lEPTB;Nj62NUBvVQ>? NIP3blRUSU6JRWK=
KP-4 M4j2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ROJRDUUN3ME23JI5O MVfTRW5ITVJ?
LU-139 NFnyWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PPdWlEPTB;Nz63O{BvVQ>? NGfRWGJUSU6JRWK=
ETK-1 NHfseGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojJTWM2OD15Lki4JI5O MYTTRW5ITVJ?
Ramos-2G6-4C10 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH1VHhKSzVyPUiuOFkhdk1? NHezTnRUSU6JRWK=
MHH-PREB-1 NGHuSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;qZ2lEPTB;OT6xNkBvVQ>? Ml;lV2FPT0WU
DU-4475 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTlwNESgcm0> M1rpNnNCVkeHUh?=
NCI-H1666 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jlTWlEPTB;OT63NUBvVQ>? MoHjV2FPT0WU
CAMA-1 NHK5cZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTlwODDuUS=> M17FcXNCVkeHUh?=
TYK-nu MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fObWlEPTB;OT65OEBvVQ>? NV65RWxsW0GQR1XS
MFE-280 NGnBRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDjTWM2OD17Lkm5JI5O M4PsdnNCVkeHUh?=
A549 NIPoR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0S5RzUUN3ME2xNE4yPCCwTR?= NETsPZdUSU6JRWK=
769-P NEXafIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rIPGlEPTB;MUCuOFQhdk1? M2D1TXNCVkeHUh?=
L-363 M4Xzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;VZ5JKSzVyPUGwMlY6KG6P M{TDVXNCVkeHUh?=
ES8 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nWTGlEPTB;MUCuPUBvVQ>? NWfac4VPW0GQR1XS
PA-1 M1:2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ONmlEPTB;MUGuPFIhdk1? MV3TRW5ITVJ?
Mewo NIPiRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3EPZV2UUN3ME2xNU46QSCwTR?= Mk\mV2FPT0WU
HSC-3 NYC0dnljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF{LkKxJI5O MlG5V2FPT0WU
H4 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHZTWM2OD1zMj62O{BvVQ>? NGTZ[4NUSU6JRWK=
BB65-RCC NUXzeFZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\GVZpKSzVyPUGyMlczKG6P NFLTNHpUSU6JRWK=
NCI-H1793 NFHMdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz5TWM2OD1zMj64NkBvVQ>? MUDTRW5ITVJ?
KARPAS-45 M2fYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTXSWNKSzVyPUGzMlUyKG6P MmC4V2FPT0WU
GCT NV3zXFNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzRbJdKSzVyPUGzMlY5KG6P NEXGbY9USU6JRWK=
EoL-1 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;qcIdKSzVyPUGzMlk{KG6P MoTXV2FPT0WU
LB2241-RCC NInBeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HqemlEPTB;MUSuNFEhdk1? Mo[3V2FPT0WU
ES5 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF2Lke0JI5O NYfxXYJpW0GQR1XS
LOXIMVI NUfRfWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2Lkm5JI5O M1nKTHNCVkeHUh?=
COR-L105 NUS4[2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF3LkC0JI5O NEXWNJpUSU6JRWK=
P12-ICHIKAWA MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSxd2xKSzVyPUG1MlEhdk1? M{W3VHNCVkeHUh?=
CHL-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vvcGlEPTB;MUWuOFUhdk1? MUHTRW5ITVJ?
VMRC-RCZ NHPRUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvKZ4JKSzVyPUG1MlY{KG6P MYHTRW5ITVJ?
HH MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF3Lkegcm0> M3fOR3NCVkeHUh?=
NUGC-3 NGrO[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLT[4NKSzVyPUG2MlM1KG6P M{fPZ3NCVkeHUh?=
EGI-1 NVvnW4dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M370Z2lEPTB;MU[uOFMhdk1? NEDHSJpUSU6JRWK=
OS-RC-2 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fHRWlEPTB;MU[uOFchdk1? NXO5[FhUW0GQR1XS
MOLT-16 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnyWHlKSzVyPUG3MlE2KG6P MXrTRW5ITVJ?
NCI-H209 M{LZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF5LkK5JI5O NFzGVZFUSU6JRWK=
697 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjPZ|ZKSzVyPUG3MlQ{KG6P M1rzPXNCVkeHUh?=
D-56MG Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\meWNVUUN3ME2xO{43QSCwTR?= MYHTRW5ITVJ?
VA-ES-BJ NELJOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHznS3FKSzVyPUG3Mlg{KG6P MVjTRW5ITVJ?
EW-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7EcoNKSzVyPUG4MlA1KG6P M{jB[HNCVkeHUh?=
HGC-27 M4i1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\sb2FKSzVyPUG4MlA3KG6P M4r3N3NCVkeHUh?=
ES7 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\qemZKSzVyPUG4MlA6KG6P MWDTRW5ITVJ?
HuH-7 M4fNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFviVIFKSzVyPUG4MlQhdk1? NHfSbXNUSU6JRWK=
BCPAP NGT3ZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD1zOD62OUBvVQ>? M364TXNCVkeHUh?=
SW1710 NEnub3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF6LkeyJI5O NWTPcINlW0GQR1XS
IST-MEL1 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULmXldnUUN3ME2xPE44PyCwTR?= NXHue|BPW0GQR1XS
SF295 NXzMU2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDm[4pKSzVyPUG4Mlk{KG6P MYPTRW5ITVJ?
RPMI-7951 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm4TWM2OD1zOT6yPEBvVQ>? M{PJ[3NCVkeHUh?=
SF126 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF7LkSxJI5O NEi0PYJUSU6JRWK=
GAMG NGP4OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXlWlJ2UUN3ME2xPU41QCCwTR?= NGrBOZBUSU6JRWK=
KNS-81-FD MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDSWlEPTB;MUmuOVQhdk1? MnXHV2FPT0WU
RT-112 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX6[FlpUUN3ME2xPU43PiCwTR?= MUfTRW5ITVJ?
DEL NIDhTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPpb21KSzVyPUKwMlQ6KG6P NF\qU2dUSU6JRWK=
CGTH-W-1 NX2zcYJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzVTWM2OD1{MD62N{BvVQ>? M2HweHNCVkeHUh?=
HOS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJzLkC2JI5O NWTiOopRW0GQR1XS
ES4 NEH4PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXkTWM2OD1{MT6wPEBvVQ>? NFvQOodUSU6JRWK=
RXF393 NWj1c5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MornTWM2OD1{MT60OUBvVQ>? MlXXV2FPT0WU
NCI-H2030 NIX1OZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPEbZJKSzVyPUKxMlUzKG6P MlixV2FPT0WU
YH-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrpTWM2OD1{MT64PEBvVQ>? NHX2XGJUSU6JRWK=
HT-1080 NVHRVIJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjRfWRSUUN3ME2yNU46OyCwTR?= MUDTRW5ITVJ?
NCI-SNU-1 NGPoUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HLWWlEPTB;MkGuPVUhdk1? NX6zTnRxW0GQR1XS
G-402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{LkG2JI5O MYTTRW5ITVJ?
786-0 NY\CWGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\QXWlEPTB;MkKuNlkhdk1? NVTYSWEyW0GQR1XS
ME-180 NVv6NIFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0TpRKSzVyPUKyMlQ{KG6P NV7rTJo2W0GQR1XS
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XqPGlEPTB;MkKuOVMhdk1? M3;kTnNCVkeHUh?=
J-RT3-T3-5 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nGU2lEPTB;MkKuPVYhdk1? MojuV2FPT0WU
TGBC1TKB M4LpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD1{Mz6wOUBvVQ>? MYLTRW5ITVJ?
SW780 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\zRWJlUUN3ME2yN{4yOyCwTR?= NUTQ[5VHW0GQR1XS
MG-63 NHm3VmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;UTWM2OD1{Mz60OUBvVQ>? MWTTRW5ITVJ?
BV-173 NV;QbG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFTY9KSzVyPUKzMlg4KG6P NXTYZVJOW0GQR1XS
CAL-51 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|Lki5JI5O NF7xR21USU6JRWK=
A375 NEHxeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L5XmlEPTB;MkOuPVMhdk1? NH7NSWVUSU6JRWK=
MEL-HO NYTuXmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS2TWM2OD1{ND6wOEBvVQ>? MnGyV2FPT0WU
EFO-27 M3rQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1U|RTUUN3ME2yOE4{OyCwTR?= MoXQV2FPT0WU
Hs-578-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ2LkW4JI5O M37n[XNCVkeHUh?=
NBsusSR M37wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLaTWM2OD1{ND62JI5O Mo[3V2FPT0WU
CTB-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzi[5lSUUN3ME2yOE43PyCwTR?= MnXLV2FPT0WU
FTC-133 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jqU2lEPTB;MkWuNUBvVQ>? NH\iWJNUSU6JRWK=
MOLT-4 NIC1UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT5d3NNUUN3ME2yOU4yOiCwTR?= MYTTRW5ITVJ?
HO-1-N-1 NEnCXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3[mlEPTB;MkWuNVUhdk1? Moi0V2FPT0WU
ES3 NHHRW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7TSlYyUUN3ME2yOU4zOiCwTR?= MlrvV2FPT0WU
TI-73 NF33eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ3LkK4JI5O M1\5enNCVkeHUh?=
MPP-89 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G0XGlEPTB;MkWuN|Ihdk1? NYHERZZiW0GQR1XS
KYSE-150 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nCTmlEPTB;MkWuPFkhdk1? MXrTRW5ITVJ?
LXF-289 NXXrVGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\NPWVoUUN3ME2yOk4xPCCwTR?= NWrtRpBRW0GQR1XS
SK-LU-1 NGjQdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ToNGlEPTB;Mk[uNVchdk1? M4TIR3NCVkeHUh?=
HOP-92 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CeVFoUUN3ME2yOk41QCCwTR?= NELhSVhUSU6JRWK=
HuO9 NVq3TlRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq1TFA6UUN3ME2yOk44PiCwTR?= NViyeYlmW0GQR1XS
SW962 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f3XGlEPTB;Mk[uO|Yhdk1? NFPaSohUSU6JRWK=
RS4-11 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULZOXFiUUN3ME2yOk46OSCwTR?= NIfHdHRUSU6JRWK=
NCI-H292 NHnW[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni3TWM2OD1{NzDuUS=> NHzCOHBUSU6JRWK=
DB NFv5VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPDTWM2OD1{Nz6zOkBvVQ>? MUjTRW5ITVJ?
SW1088 NUDGS|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ6LkK5JI5O MXvTRW5ITVJ?
A204 M4LXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ6LkS3JI5O NX[5eY8zW0GQR1XS
A3-KAW Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jDRWlEPTB;MkiuOlQhdk1? M3vPSnNCVkeHUh?=
MV-4-11 NH7pVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ6Lkegcm0> M1[2N3NCVkeHUh?=
ES1 M17aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonLTWM2OD1{OD64OEBvVQ>? MoDmV2FPT0WU
ONS-76 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHDZoVPUUN3ME2yPU4xPSCwTR?= NHPGTnJUSU6JRWK=
D-263MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrSTWM2OD1{OT6zOUBvVQ>? M4fLcHNCVkeHUh?=
U-2-OS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37a[2lEPTB;MkmuOUBvVQ>? Mn\zV2FPT0WU
T98G NWXvOVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;sUmlEPTB;MkmuPFghdk1? NXe1R|ZPW0GQR1XS
GI-ME-N NI\r[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ7LkmxJI5O NVjIb|BqW0GQR1XS
BHT-101 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNyLkC1JI5O NXPrXoE3W0GQR1XS
NOS-1 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNyLkGyJI5O M3jTXnNCVkeHUh?=
AsPC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PsdGlEPTB;M{CuNkBvVQ>? M33IXnNCVkeHUh?=
QIMR-WIL Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLaS3RnUUN3ME2zNE43KG6P MkLQV2FPT0WU
JVM-3 NYXWOIFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TK[WlEPTB;M{CuPFMhdk1? NV3XSmhwW0GQR1XS
KU-19-19 NVK2NJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofpTWM2OD1|MT6xN{BvVQ>? NELFOXlUSU6JRWK=
OVCAR-8 M13je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HBZmlEPTB;M{GuNlYhdk1? MUfTRW5ITVJ?
BEN NXS2TZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjRdIZKSzVyPUOxMlY{KG6P M{HlcnNCVkeHUh?=
BE-13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2yPYNKUUN3ME2zNU45OiCwTR?= M1vrfXNCVkeHUh?=
EW-18 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13MeGlEPTB;M{GuPFYhdk1? NVTFN4NoW0GQR1XS
ECC10 NUD3[GdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPTZnV5UUN3ME2zNU46PSCwTR?= MojZV2FPT0WU
CTV-1 M4TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3LbpdKSzVyPUOyMlgzKG6P NHOxWoFUSU6JRWK=
COLO-800 M1XwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP6U4tKSzVyPUOyMlkzKG6P MoDXV2FPT0WU
A2058 NX36V|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN|LkK1JI5O NYS1TngyW0GQR1XS
VM-CUB-1 NF3OfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHqTVdUUUN3ME2zN{41OyCwTR?= NVG0SlBjW0GQR1XS
Ca9-22 M{\3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZU2lKSzVyPUOzMlU2KG6P Mn\xV2FPT0WU
COLO-684 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnWTWM2OD1|Mz61PEBvVQ>? M4LzZnNCVkeHUh?=
RPMI-8226 M1XZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnQVVJKSzVyPUOzMlgzKG6P NWT2RmVwW0GQR1XS
SK-NEP-1 NFWzfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTN2LkG1JI5O M1fRSHNCVkeHUh?=
Becker MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN2LkKxJI5O M1vMcHNCVkeHUh?=
NCI-H28 M{\qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrDPGNKSzVyPUO0MlQ1KG6P M4DsOHNCVkeHUh?=
CAL-120 NUnnTXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN2LkeyJI5O NXTWdnN[W0GQR1XS
MDA-MB-157 NUHETFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT1bpJKSzVyPUO1MlQyKG6P Mle1V2FPT0WU
OVCAR-5 NUOwW|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXwTYpWUUN3ME2zOU41PyCwTR?= MlX1V2FPT0WU
LAMA-84 NYrLO5FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyXohKSzVyPUO1Mlg4KG6P NF\MSFNUSU6JRWK=
CAKI-1 M1P5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TLSGlEPTB;M{[uOFMhdk1? NXriNZVnW0GQR1XS
Daoy Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYdlBKSzVyPUO2Mlchdk1? M1THe3NCVkeHUh?=
CAL-62 MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W0WmlEPTB;M{[uPFYhdk1? MljhV2FPT0WU
8-MG-BA MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;nTWM2OD1|Nz6yOUBvVQ>? MVfTRW5ITVJ?
8505C NWLVVnNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVdXFKSzVyPUO3MlUyKG6P M1jYPHNCVkeHUh?=
LNCaP-Clone-FGC M13wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG3ZWlKSzVyPUO3MlU6KG6P NIrUU4hUSU6JRWK=
CAL-39 NELP[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN5Lkmgcm0> NX30R2N[W0GQR1XS
MN-60 NITaSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjVR2RKSzVyPUO3Mlk3KG6P Mnj4V2FPT0WU
RKO M3zZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn1cndlUUN3ME2zPE4{OyCwTR?= MkPQV2FPT0WU
U251 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7iTWM2OD1|OD60N{BvVQ>? M4HGXHNCVkeHUh?=
SJSA-1 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN6LkW0JI5O NFO4W5FUSU6JRWK=
CAL-12T MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XzXGlEPTB;M{iuOkBvVQ>? MYXTRW5ITVJ?
HCC1419 NEDZbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLTepRwUUN3ME2zPE44OSCwTR?= NUj2e5B7W0GQR1XS
CO-314 NX7VOIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN6Lke0JI5O M3jUOHNCVkeHUh?=
LB1047-RCC M{TTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PTSGlEPTB;M{iuPFEhdk1? MojyV2FPT0WU
A101D NHLQPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN6Lkm3JI5O NXXGbJZ2W0GQR1XS
MDA-MB-175-VII NVroW3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWwS5FKSzVyPUO5MlUyKG6P NF\ETlZUSU6JRWK=
MZ2-MEL Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD0TWM2OD1|OT62OkBvVQ>? MVLTRW5ITVJ?
NB5 NHXDbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThfIpsUUN3ME20NE43PCCwTR?= M{LkXnNCVkeHUh?=
G-401 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DSO2lEPTB;NECuPFIhdk1? NFXodGlUSU6JRWK=
HT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH34[HVKSzVyPUSxMlAzKG6P M4PRbHNCVkeHUh?=
8305C MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRzLki3JI5O NFTSS2hUSU6JRWK=
BHY MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33kSmlEPTB;NEKuO|Ihdk1? NXrGUFN[W0GQR1XS
NTERA-S-cl-D1 M1HNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTCOG1KSzVyPUSzJI5O MonHV2FPT0WU
T-24 NHfoOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jhUWlEPTB;NEOuPFMhdk1? NYL4cIJXW0GQR1XS
EPLC-272H NWDRe48{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzrTWM2OD12ND6zPUBvVQ>? M1PDN3NCVkeHUh?=
PSN1 NWOxcoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR2LkSgcm0> NYrkfo5IW0GQR1XS
NCI-H2452 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXVTWM2OD12ND61PEBvVQ>? MV;TRW5ITVJ?
KS-1 NHLNSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfF[GNKSzVyPUS0MlY3KG6P MoTmV2FPT0WU
HD-MY-Z MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nUe2lEPTB;NESuPVIhdk1? MmHFV2FPT0WU
KNS-62 M1vlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR3LkO4JI5O NYPGRlh6W0GQR1XS
NOMO-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR3Lki3JI5O NV:zNWI5W0GQR1XS
SK-HEP-1 M33ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\aTWM2OD12Nj6wOEBvVQ>? M3XLRnNCVkeHUh?=
IGR-1 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpTZpKSzVyPUS2MlE{KG6P NVvPVVlLW0GQR1XS
KYSE-180 NIPoeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR4LkG3JI5O NI\NNYtUSU6JRWK=
EW-22 M17XS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR4LkKgcm0> NH25RlhUSU6JRWK=
NCI-H1355 M1rX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR4LkO0JI5O MVzTRW5ITVJ?
DOHH-2 NVvBTpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXTWYE1UUN3ME20Ok4{PyCwTR?= Mk\ZV2FPT0WU
A4-Fuk Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TVVmlEPTB;NE[uOVIhdk1? M2rGVXNCVkeHUh?=
PC-14 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP3TWM2OD12Nj61O{BvVQ>? MnrsV2FPT0WU
TE-5 NV3DSI93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR4Lki0JI5O M2jXc3NCVkeHUh?=
LB996-RCC M2K3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T3XmlEPTB;NEeuNVkhdk1? MmiwV2FPT0WU
NCI-H1623 NHfZVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIS2lEPTB;NEeuO|Yhdk1? MYjTRW5ITVJ?
NCI-H1155 M2HuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImz[W9KSzVyPUS4MlMzKG6P NUS3T4xtW0GQR1XS
LoVo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3VV3h2UUN3ME20PE41KG6P MYDTRW5ITVJ?
MCF7 NXHwcZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMbld[UUN3ME20PE42QCCwTR?= MmnvV2FPT0WU
AGS MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR6Lke3JI5O MoH3V2FPT0WU
PFSK-1 M1L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP3TWM2OD12OT6wOkBvVQ>? MlTTV2FPT0WU
22RV1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:3TWM2OD12OT6wPUBvVQ>? NX:1cnZbW0GQR1XS
COR-L23 NHLBSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVznfWN5UUN3ME20PU4yPiCwTR?= MVHTRW5ITVJ?
D-283MED M2LFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX33bmRtUUN3ME20PU43OSCwTR?= NXvycnF[W0GQR1XS
SW982 NUnrNnR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO1O5htUUN3ME20PU46OSCwTR?= MYXTRW5ITVJ?
SW620 NUO0V|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzXGlEPTB;NUCuN|Yhdk1? MUPTRW5ITVJ?
KYSE-140 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTVyLkW1JI5O NVTNRZgxW0GQR1XS
GCIY M1f0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHse|ZyUUN3ME21NE43PyCwTR?= MX7TRW5ITVJ?
MHH-ESS-1 NFqxTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5ZYFKSzVyPUWxMlk2KG6P MUnTRW5ITVJ?
D-423MG MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXxXWxQUUN3ME21Nk4xQCCwTR?= M3XyXnNCVkeHUh?=
SF539 NXfBZXkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTV{LkO1JI5O NInYcYFUSU6JRWK=
RPMI-2650 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0RoJ5UUN3ME21Nk43QSCwTR?= NFfvSFhUSU6JRWK=
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfqNVJEUUN3ME21Nk45PyCwTR?= NYPkVXFkW0GQR1XS
YKG-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYruem15UUN3ME21N{BvVQ>? NXfQe4k4W0GQR1XS
SK-MES-1 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme4TWM2OD13Mz6yOkBvVQ>? Mm\TV2FPT0WU
HLE NEnxRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELzcJZKSzVyPUWzMlQ4KG6P M1O5d3NCVkeHUh?=
RVH-421 NXjBeIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTV|Lk[3JI5O MV;TRW5ITVJ?
C32 M4LSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTV|LkizJI5O MnnCV2FPT0WU
GB-1 NFWwU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTOSYhKSzVyPUW0MlIhdk1? MXzTRW5ITVJ?
SNB75 NXjsfIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHHVY1KSzVyPUW0MlI3KG6P M4\rRnNCVkeHUh?=
EM-2 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorTTWM2OD13ND60JI5O NIDXOFlUSU6JRWK=
RH-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXOV4VKSzVyPUW0Mlchdk1? MnLsV2FPT0WU
NKM-1 M1;6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33GUGlEPTB;NUSuPFEhdk1? NWDyOJB4W0GQR1XS
NCI-H2405 NELTO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;OTWM2OD13ND64PEBvVQ>? M1\3cnNCVkeHUh?=
KYSE-450 NITMfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjiTXNKSzVyPUW1MlE3KG6P MnTtV2FPT0WU
A704 M1zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32xeWlEPTB;NUWuOVkhdk1? M3XWZXNCVkeHUh?=
HAL-01 NV7nTI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomzTWM2OD13NT64N{BvVQ>? MlPaV2FPT0WU
TE-11 NHjRWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j6NWlEPTB;NUWuPVkhdk1? MWXTRW5ITVJ?
DOK NX7oSolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnBSFNKSzVyPUW2MlAzKG6P MVnTRW5ITVJ?
KY821 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m1UmlEPTB;NU[uNkBvVQ>? MVfTRW5ITVJ?
KGN MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDCd|FKSzVyPUW2MlMzKG6P M1HuRnNCVkeHUh?=
MC116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvRTWM2OD13Nz64JI5O NFG4UXVUSU6JRWK=
PANC-08-13 NYLROYZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi0fmx2UUN3ME21PE4xOSCwTR?= MljVV2FPT0WU
KE-37 NFH2fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzS5NKSzVyPUW4Mlc4KG6P NWrHZlhsW0GQR1XS
KYSE-410 NXe2V4sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3Xm5UUUN3ME21PU41PyCwTR?= MXTTRW5ITVJ?
RO82-W-1 M3rYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmftTWM2OD13OT65JI5O NFjKRZlUSU6JRWK=
M14 M2jEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDFTWM2OD14MD6wOEBvVQ>? NEXI[G9USU6JRWK=
GI-1 NHjQe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIntSYlKSzVyPU[wMlMhdk1? NF7KfoRUSU6JRWK=
ML-2 M4rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZyLk[yJI5O NVvCdZFMW0GQR1XS
BFTC-905 NHHZfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5TWM2OD14MD62OUBvVQ>? M3nXU3NCVkeHUh?=
DMS-273 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjxR2xKSzVyPU[wMlg4KG6P M2WzVnNCVkeHUh?=
MDA-MB-361 M2q0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMbWtKSzVyPU[xJI5O NWrtTpdpW0GQR1XS
MSTO-211H MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZNWlEPTB;NkOuOVEhdk1? NXXrdVJGW0GQR1XS
MEG-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZ|LkWyJI5O MlX3V2FPT0WU
M059J NGfBeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3XHpWUUN3ME22N{42QCCwTR?= NEPDdZVUSU6JRWK=
LN-405 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZ|Lki1JI5O MXHTRW5ITVJ?
NCI-H1581 M3jCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\lXWlEPTB;NkSuNFMhdk1? NUfqdWtFW0GQR1XS
TCCSUP NEfrZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXZ[3RKSzVyPU[0MlU{KG6P NVXiR5VnW0GQR1XS
SW872 NG[0cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED1SXlKSzVyPU[0MlU4KG6P MUHTRW5ITVJ?
KYSE-510 NXXPcYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPae2xKSzVyPU[1Mlc2KG6P MnHoV2FPT0WU
NCI-H1792 NYfzenVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLxeHNYUUN3ME22Ok4yPSCwTR?= NUm4b4xGW0GQR1XS
SW13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxUHF1UUN3ME22Ok42KG6P MWrTRW5ITVJ?
TE-8 M3PKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLJWpNyUUN3ME22Ok42OiCwTR?= MmrMV2FPT0WU
SCH NUHPXGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL6TWM2OD14Nz6xJI5O NEDDV2tUSU6JRWK=
NEC8 NF3WXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrGdHBKSzVyPU[3MlI1KG6P NGDIbZRUSU6JRWK=
HuO-3N1 NW\YZ|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfTTWM2OD14Nz6zNUBvVQ>? NFvTfFlUSU6JRWK=
EFM-19 NUezT5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZ5LkWgcm0> NUDIZZdkW0GQR1XS
HEC-1 M1exOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\DU2lEPTB;NkeuOVIhdk1? Mnq0V2FPT0WU
T47D NWX5UHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuzUFdKSzVyPU[3Mlg4KG6P Mn3LV2FPT0WU
SNU-423 NHvXcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnZWmtKSzVyPU[3Mlk5KG6P MojCV2FPT0WU
WM-115 M12xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFThNZVKSzVyPU[4MlE1KG6P M{L1fnNCVkeHUh?=
CaR-1 M2LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjGTWM2OD14OD6yOUBvVQ>? M1jMVHNCVkeHUh?=
KU812 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTZ6Lk[5JI5O NVezeXM4W0GQR1XS
AM-38 NHr4N2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTZ7LkOxJI5O NIi4bYtUSU6JRWK=
KOSC-2 M1nvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fONmlEPTB;NkmuPVchdk1? NF7U[olUSU6JRWK=
MC-IXC NGnCOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvtTWM2OD15MD6wPEBvVQ>? NFGwZW1USU6JRWK=
SCC-4 M37vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TK[WlEPTB;N{GuN|ghdk1? MVzTRW5ITVJ?
Calu-3 NY\ZVo02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFV4F4UUN3ME23NU46QCCwTR?= M4j5bHNCVkeHUh?=
RPMI-8866 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD15Mj64NkBvVQ>? M{jjZXNCVkeHUh?=
OVCAR-4 M4fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXxW5JKSzVyPUezMlM3KG6P MmHEV2FPT0WU
OAW-42 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS5fVJ4UUN3ME23N{4{QSCwTR?= NWSwWFJGW0GQR1XS
ATN-1 NIjvTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\QPVhJUUN3ME23N{45PyCwTR?= Mmf0V2FPT0WU
CHP-212 NYnMdFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD15ND65OUBvVQ>? MUfTRW5ITVJ?
C2BBe1 NEfYSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC3TWM2OD15NT6wN{BvVQ>? NX\6enZNW0GQR1XS
A498 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PSSWlEPTB;N{WuNVUhdk1? NHO0[GpUSU6JRWK=
SH-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H0RmlEPTB;N{WuNlEhdk1? MlTQV2FPT0WU
SNU-449 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyTWM2OD15NT63PUBvVQ>? NHvYd49USU6JRWK=
RD Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTd3Lki2JI5O NXXHU3N2W0GQR1XS
PANC-03-27 M{T1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTd4LkK1JI5O NH7oe5JUSU6JRWK=
S-117 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTd4LkK3JI5O MlvvV2FPT0WU
SK-MEL-2 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO3SZh{UUN3ME23Ok44PSCwTR?= MYTTRW5ITVJ?
LK-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP6TWM2OD15Nz6wOUBvVQ>? MXvTRW5ITVJ?
CP50-MEL-B M13qZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7YU3hKSzVyPUe3MlQhdk1? NWm3UoJMW0GQR1XS
647-V NYSyXllST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXiybZJ5UUN3ME23PE4xPyCwTR?= NWTNZYFKW0GQR1XS
LU-134-A M1TsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkTWM2OD15OT6wN{BvVQ>? M3HC[XNCVkeHUh?=
5637 NHHRdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWTWM2OD15OT6yN{BvVQ>? MUXTRW5ITVJ?
NCI-H1437 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\yTIFFUUN3ME24NE42KG6P M1zMfXNCVkeHUh?=
NCI-H460 NIPyVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThzLkKzJI5O M{TsfnNCVkeHUh?=
BxPC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHToVo1KSzVyPUixMlQ3KG6P NYLoO5R6W0GQR1XS
CAN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTv[2lXUUN3ME24NU45PCCwTR?= NGXsTlVUSU6JRWK=
KINGS-1 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvQOmljUUN3ME24Nk4{OiCwTR?= MXXTRW5ITVJ?
OCUB-M NEO3[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XIfmlEPTB;OEKuOFEhdk1? M2P2ZXNCVkeHUh?=
KALS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTh{LkW0JI5O MojjV2FPT0WU
OCI-AML2 NIrMUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTh{Lk[xJI5O NVL1ZYd5W0GQR1XS
A253 NYLPWIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHMTWM2OD16Mj62OUBvVQ>? NH;QV|hUSU6JRWK=
LCLC-97TM1 NX3DcWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nTbmlEPTB;OEKuPFYhdk1? NWnR[FdQW0GQR1XS
NCI-H520 NXLF[pFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\LOmlEPTB;OEOuNFYhdk1? MUPTRW5ITVJ?
P30-OHK NH3qUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[zfJpKSzVyPUizMlUhdk1? NV3kbm1wW0GQR1XS
SBC-5 M3XKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTh|LkWyJI5O NFexc4NUSU6JRWK=
HCE-T MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\0TWM2OD16Mz63OEBvVQ>? MXHTRW5ITVJ?
JEG-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4[G9JUUN3ME24OE4yKG6P NULk[pJwW0GQR1XS
KG-1 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QXIdKSzVyPUi0MlI1KG6P M2fNVHNCVkeHUh?=
MIA-PaCa-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fWPGlEPTB;OESuOVQhdk1? NVWzbW9YW0GQR1XS
CAL-33 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXxTWM2OD16NT6wPEBvVQ>? MXrTRW5ITVJ?
639-V NUfwNHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jLUWlEPTB;OEWuOFIhdk1? NX3RTVJIW0GQR1XS
NCI-H1048 NFXGZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vIOWlEPTB;OE[uN|Ehdk1? MX3TRW5ITVJ?
NCI-H1573 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnGTppKSzVyPUi3MlQ5KG6P M{juZnNCVkeHUh?=
NCI-H2228 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDkdpA1UUN3ME24PE4zPiCwTR?= MkL2V2FPT0WU
NB14 M{PKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTh6LkOgcm0> NV[wZnc{W0GQR1XS
SCC-25 M{XUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fINGlEPTB;OEmuPFIhdk1? NGTneY1USU6JRWK=
A431 M3HYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTQNFB3UUN3ME24PU46PyCwTR?= M{XVSXNCVkeHUh?=
SN12C M2\tfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfyTWM2OD17MD62NkBvVQ>? MUfTRW5ITVJ?
HuCCT1 NXvvTnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfETWM2OD17MD63OkBvVQ>? M{\jbXNCVkeHUh?=
LS-123 NFf2R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5TWM2OD17Mj6xPEBvVQ>? MlvtV2FPT0WU
CAL-85-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTl{LkS4JI5O NV7mepZYW0GQR1XS
ES6 M1L6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITvNXlKSzVyPUmyMlg{KG6P MkjsV2FPT0WU
NCI-H650 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe1SVhKSzVyPUm0MlA6KG6P MWTTRW5ITVJ?
NCI-H446 NGHuWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTl3LkGyJI5O NXTSbnQyW0GQR1XS
EW-13 NUDiW2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHGTWM2OD17NT63OUBvVQ>? MUXTRW5ITVJ?
HSC-2 NVPWWphMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkTmlEPTB;OUWuPFkhdk1? MY\TRW5ITVJ?
U031 NEfPdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFywPVhKSzVyPUm2Mlc{KG6P M1HpbHNCVkeHUh?=
EW-11 M4fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofoTWM2OD17Nj64PEBvVQ>? NF;qeZhUSU6JRWK=
GAK NGC5OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THZ2lEPTB;OUiuPVMhdk1? NFrPenBUSU6JRWK=
SK-OV-3 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTSTYFJUUN3ME2xNFAvODdibl2= MnvtV2FPT0WU
OMC-1 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HVbGlEPTB;MUCwMlE5KG6P M3;sU3NCVkeHUh?=
TK10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyMD6yNUBvVQ>? M1HRTnNCVkeHUh?=
EKVX M2nWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Xi[mlEPTB;MUCwMlYhdk1? NV[wfog{W0GQR1XS
Detroit562 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj0TWM2OD1zMEKuNVchdk1? NWrGV2dGW0GQR1XS
SF268 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H0VmlEPTB;MUCyMlM1KG6P NUThZWVKW0GQR1XS
SNU-387 NVzQRYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFyND6xO{BvVQ>? NEj1SZZUSU6JRWK=
MDA-MB-231 M2PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjtXmZKSzVyPUGwOU4xPiCwTR?= NVjYTVN{W0GQR1XS
NCI-H1563 NInwT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr4[2RWUUN3ME2xNFUvOThibl2= NWj6VlhQW0GQR1XS
D-502MG NIWxdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyNT63JI5O M33m[XNCVkeHUh?=
A2780 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHR|JKSzVyPUGwOk41PyCwTR?= M{LuWHNCVkeHUh?=
IA-LM NHTqNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzMdZY1UUN3ME2xNFcvPTFibl2= NYPybmh6W0GQR1XS
D-392MG NHPE[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[zcHZKSzVyPUGwO{42PCCwTR?= MoXCV2FPT0WU
MS-1 NXzqOWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkixTWM2OD1zMEeuO|Ehdk1? NIO4N25USU6JRWK=
SW1990 NGLldJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\LTWM2OD1zMEiuOVQhdk1? MkLwV2FPT0WU
HEL MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXaSZhrUUN3ME2xNFkvOjlibl2= NYLSOIRoW0GQR1XS
SW1573 NF7ZcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\j[5VKSzVyPUGwPU4{OSCwTR?= MVTTRW5ITVJ?
SW1783 NV\XOIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3OOWdKSzVyPUGxNE4zOiCwTR?= MkfpV2FPT0WU
COLO-680N M1jzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HQRWlEPTB;MUGwMlc3KG6P MUXTRW5ITVJ?
NCI-N87 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzMT6wOEBvVQ>? MoLqV2FPT0WU
SK-MEL-28 NIjpRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHUTWM2OD1zMUGuOVUhdk1? M1;rVHNCVkeHUh?=
BT-20 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXvZ4RKSzVyPUGxNk4xOSCwTR?= MY\TRW5ITVJ?
NCI-H1648 M{HMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrSVJc3UUN3ME2xNVMhdk1? NH3kR3BUSU6JRWK=
no-11 M1HESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke2TWM2OD1zMUOuNlghdk1? MkHaV2FPT0WU
MOLT-13 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LqeWlEPTB;MUGzMlQ1KG6P NEe1TI1USU6JRWK=
NCI-H2170 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFzND61NUBvVQ>? M2n0fXNCVkeHUh?=
HTC-C3 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYTWM2OD1zMU[uPFUhdk1? M3nIOXNCVkeHUh?=
LU-99A MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\PUGlEPTB;MUG3MlIyKG6P MmTYV2FPT0WU
HCC2998 NGniTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7MUo5KSzVyPUGxO{46OiCwTR?= MV3TRW5ITVJ?
NB13 NHjHeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDuR|FyUUN3ME2xNVcvQTlibl2= NVzDPFlYW0GQR1XS
GT3TKB NIrj[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFzOD6wPEBvVQ>? NUfKUFlHW0GQR1XS
BT-549 NITORo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrRTWM2OD1zMUiuPVUhdk1? NV3peJV5W0GQR1XS
NCI-H747 NIjTS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLNd5JKSzVyPUGxPU4{PCCwTR?= Ml23V2FPT0WU
EW-1 M2XUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMe49mUUN3ME2xNlAvOiCwTR?= M4KydXNCVkeHUh?=
LB831-BLC Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\jTWM2OD1zMkCuOlMhdk1? NX\JZXN3W0GQR1XS
NMC-G1 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF{MT6xNUBvVQ>? NX\wW4VLW0GQR1XS
COLO-679 NUHNXWhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4TWM2OD1zMkKuNVUhdk1? NIr4NJhUSU6JRWK=
HL-60 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULkfldlUUN3ME2xNlMvOSCwTR?= M2XP[XNCVkeHUh?=
MKN7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfYS|VNUUN3ME2xNlMvQDNibl2= MoX6V2FPT0WU
RERF-LC-MS M{C5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jGTmlEPTB;MUK0MlMyKG6P MnuzV2FPT0WU
DMS-114 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITxRmdKSzVyPUGyOU4xQSCwTR?= MUTTRW5ITVJ?
HuP-T4 NV3ncmp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnreJh3UUN3ME2xNlYvQTdibl2= NXrSSpdrW0GQR1XS
HCC2157 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXZ[5BKSzVyPUGyO{42KG6P NHLURpZUSU6JRWK=
SKG-IIIa M2LJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\uTWM2OD1zMkiuPEBvVQ>? MkG0V2FPT0WU
HCT-116 M2XzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ITWM2OD1zM{CuOlQhdk1? NH7G[YdUSU6JRWK=
BB30-HNC NYHZcGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojyTWM2OD1zM{CuO|ghdk1? MnnQV2FPT0WU
KYSE-270 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF|MD64PEBvVQ>? NYe0Z3lGW0GQR1XS
MFM-223 NXzHSFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3sTWM2OD1zM{GuOVEhdk1? NHz3[I5USU6JRWK=
NH-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4dGlEPTB;MUOyMlk6KG6P MYHTRW5ITVJ?
U-118-MG NEnicpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTVNWhbUUN3ME2xN|MvPjJibl2= MmTWV2FPT0WU
ESS-1 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4WWlEPTB;MUO1MlE5KG6P MVTTRW5ITVJ?
D-247MG Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzR[phoUUN3ME2xN|UvOjFibl2= NIC3NGhUSU6JRWK=
IGROV-1 NGfhUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLQWFFsUUN3ME2xN|UvPzZibl2= M2nOWXNCVkeHUh?=
C-33-A M3LnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|NT65O{BvVQ>? M3y5SXNCVkeHUh?=
NCI-H1693 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF|Nj6xNkBvVQ>? M1vZT3NCVkeHUh?=
MLMA NGjBWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnk[JNUUUN3ME2xN|YvPThibl2= MkXZV2FPT0WU
SK-N-AS NXLrVWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[wRnlSUUN3ME2xN|cvOTdibl2= NGPmfYtUSU6JRWK=
NCI-H1755 NXXvXXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF|OD64OUBvVQ>? Ml35V2FPT0WU
CHP-134 NFu1OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmzUlhKSzVyPUGzPU42PSCwTR?= MXzTRW5ITVJ?
LS-513 M17zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXRTWM2OD1zNECuPVEheE1? NXLzXXJFW0GQR1XS
TE-12 M4XEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF2MD65N{BvVQ>? MV;TRW5ITVJ?
KNS-42 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOwTWM2OD1zNESuN{BvVQ>? MW\TRW5ITVJ?
SJRH30 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f1V2lEPTB;MUS0MlQ1KG6P Mlf6V2FPT0WU
NCI-H1092 NHnrfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjwTWM2OD1zNESuOVIhdk1? Mo\OV2FPT0WU
H-EMC-SS NHHWV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj2Z4dKSzVyPUG0Ok45OSCwTR?= MYXTRW5ITVJ?
SK-MEL-3 M1zRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjSfFRKSzVyPUG0O{42PSCwTR?= M4fsTXNCVkeHUh?=
SK-N-FI M1fCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHnOZdKSzVyPUG0O{42QSCwTR?= Mk\nV2FPT0WU
NCI-H2126 M{DHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfmOG5NUUN3ME2xOFgvOTVibl2= M3\he3NCVkeHUh?=
NCI-H1299 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG5PFVKSzVyPUG1NE4zOiCwTR?= NWWweHF6W0GQR1XS
CFPAC-1 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGxVVBKSzVyPUG1NE43PiCwTR?= M4PlcHNCVkeHUh?=
NCI-H661 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF3MT6yOkBvVQ>? MlPIV2FPT0WU
KYSE-70 M1:3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rSTWlEPTB;MUWxMlc6KG6P MXTTRW5ITVJ?
SW900 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvIOo1{UUN3ME2xOVQvPjVibl2= M2XXbXNCVkeHUh?=
Ca-Ski MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnoRlNKSzVyPUG1Ok4{QSCwTR?= M1LoVnNCVkeHUh?=
HPAF-II MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF3Nj60O{BvVQ>? NWTUO5R[W0GQR1XS
LB2518-MEL MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v2bmlEPTB;MUW3MlEhdk1? MnLJV2FPT0WU
LC-2-ad NU[1T|F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;NTWM2OD1zNUiuOlIhdk1? NV\Jc4dOW0GQR1XS
HCC1806 NVPCdJNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF4Nz64PEBvVQ>? NFzDbopUSU6JRWK=
UACC-62 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITxdXdKSzVyPUG2PE4xQSCwTR?= NX;hZnk5W0GQR1XS
KM-H2 NVTaSJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvvTWM2OD1zN{CuOVghdk1? NF;WOpdUSU6JRWK=
NCI-H2347 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLkTWM2OD1zN{KuO|Ihdk1? NEKyb5NUSU6JRWK=
SCC-15 NXHSPJBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrOVVVSUUN3ME2xO|MvPjZibl2= NHjiPFFUSU6JRWK=
BB49-HNC NUH3[2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ReIhZUUN3ME2xO|MvQDFibl2= MmnCV2FPT0WU
GMS-10 NFnDRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7kPJNyUUN3ME2xO|MvQTRibl2= NIjMcHVUSU6JRWK=
NCI-H2052 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xp[mlEPTB;MUe0Mlkhdk1? NXzzSJNwW0GQR1XS
SW626 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojwTWM2OD1zN{[uNFYhdk1? M4rONnNCVkeHUh?=
MDA-MB-415 NVr0TZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;2TWM2OD1zN{[uOlEhdk1? NFfoc5BUSU6JRWK=
Saos-2 NHraeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm0PVlyUUN3ME2xO|kvOzVibl2= M3rPeXNCVkeHUh?=
DK-MG NXzTbZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvGTWM2OD1zOECuN{BvVQ>? NXTXUVNpW0GQR1XS
SNU-C2B MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7wR3I3UUN3ME2xPFAvPzNibl2= NUP0cVhrW0GQR1XS
A427 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33FWmlEPTB;MUiyMlU4KG6P MY\TRW5ITVJ?
KP-N-YS MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPSN3BKSzVyPUG4OUBvVQ>? NVzDeGQ5W0GQR1XS
J82 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3WFdKSzVyPUG4OU4yQCCwTR?= NGXMVZFUSU6JRWK=
LS-411N NV;sN3pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj4TWM2OD1zOEeuNlghdk1? M3rHN3NCVkeHUh?=
HCC1937 NGm0Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i4RWlEPTB;MUi3MlQ6KG6P MnXxV2FPT0WU
OE33 M13nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrjNIpKSzVyPUG4PE46PyCwTR?= MnXwV2FPT0WU
NB7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS3TWM2OD1zOEmuPFkhdk1? MVHTRW5ITVJ?
SW684 NGPqVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4[lVvUUN3ME2xPVYvOTNibl2= MoqwV2FPT0WU
HT-144 NF;QbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF7Nj6xOUBvVQ>? M2DobnNCVkeHUh?=
SK-MEL-30 NGjYR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7pTWM2OD1zOU[uNkBvVQ>? Ml;OV2FPT0WU
DBTRG-05MG MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLyTGhkUUN3ME2xPVgvPDdibl2= NH3ReHhUSU6JRWK=
NCI-H1395 NV2wXVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K3fmlEPTB;MUm4Mlg2KG6P MVnTRW5ITVJ?
NCI-H2122 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0XmlEPTB;MkCwMlU6KG6P M3G0XHNCVkeHUh?=
no-10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTsVZE4UUN3ME2yNFEvODRibl2= MYXTRW5ITVJ?
SW48 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXvTWM2OD1{MEGuN|Ehdk1? M4jrWnNCVkeHUh?=
NCI-H1650 NGfGeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJyND6wNUBvVQ>? M{m4OXNCVkeHUh?=
MZ1-PC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHK[5dKSzVyPUKwOU42QCCwTR?= M3PG[3NCVkeHUh?=
U-266 M2K2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyy[HlKSzVyPUKwOU44QSCwTR?= MXvTRW5ITVJ?
CAS-1 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjJTWM2OD1{MEeuOFQhdk1? MV;TRW5ITVJ?
AU565 NVHLOFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJzMj64NkBvVQ>? MorIV2FPT0WU
UACC-257 NGf6PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2b4RIUUN3ME2yNVMvQTlibl2= MULTRW5ITVJ?
CAL-27 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX0XGlSUUN3ME2yNVcvODVibl2= NF\KSGVUSU6JRWK=
NCI-H23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2S|dKSzVyPUKxPU4{OyCwTR?= MVTTRW5ITVJ?
TE-6 NIDKfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojrTWM2OD1{MUmuOlghdk1? M3r0WHNCVkeHUh?=
TGBC24TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7zTWM2OD1{MkKuNVchdk1? Mlf1V2FPT0WU
TE-1 NFXTfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ntUGlEPTB;MkKyMlg5KG6P M3fLZXNCVkeHUh?=
RCC10RGB NEPMNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ{ND6xPUBvVQ>? MVLTRW5ITVJ?
NCI-H596 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfxTWM2OD1{MkiuNlIhdk1? NILRUYZUSU6JRWK=
SW954 M2Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTWZlJRUUN3ME2yN|MvQDNibl2= MULTRW5ITVJ?
NCI-H2087 NGT3e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn4OG9KSzVyPUKzOE42OSCwTR?= MYfTRW5ITVJ?
SK-PN-DW MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PjfGlEPTB;MkO1MlE6KG6P NHG5bGxUSU6JRWK=
KM12 NUXOXpVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f1SGlEPTB;MkO1Mlchdk1? M33n[XNCVkeHUh?=
BT-474 MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rIWWlEPTB;MkO1Mlc{KG6P NGDrUWtUSU6JRWK=
IST-MES1 NV\tN5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXBTWM2OD1{M{[uOVchdk1? NVHYOmpIW0GQR1XS
HT-1197 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ|OD6wPUBvVQ>? M1y5VHNCVkeHUh?=
CAL-54 NVzjOWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD1{M{iuOFkhdk1? M4LLZnNCVkeHUh?=
NB10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHUO3BKSzVyPUK0NE4xPiCwTR?= M2C3[XNCVkeHUh?=
PANC-10-05 NYHKT3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrSTWM2OD1{NEWuOVYhdk1? MYHTRW5ITVJ?
NCI-H522 M2mzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ2OD6zNUBvVQ>? MYjTRW5ITVJ?
A388 NHnBUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ2OT64NkBvVQ>? NFTyXphUSU6JRWK=
GOTO M2HCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDxepFKSzVyPUK1NE4zQSCwTR?= MnPEV2FPT0WU
KLE M{jVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDZTWM2OD1{NUGuPFchdk1? M3q4b3NCVkeHUh?=
KYSE-520 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ3Mj64OkBvVQ>? NG[wVmxUSU6JRWK=
HCE-4 NUnWPIYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7o[|JKSzVyPUK2Nk42KG6P NX74c5NNW0GQR1XS
KURAMOCHI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPZfIhKSzVyPUK2OU46KG6P NYDIbVV2W0GQR1XS
HCC38 NX\KS4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33LVGlEPTB;Mk[2MlQ5KG6P MYTTRW5ITVJ?
FADU MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fvTWlEPTB;Mk[2MlY{KG6P MVPTRW5ITVJ?
CW-2 M1XGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;UNJN7UUN3ME2yOlkvQTZibl2= MYLTRW5ITVJ?
L-428 NVLWW3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn3[Yx6UUN3ME2yO|UvOTVibl2= NWPoTZZIW0GQR1XS
HCC1569 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj2TWM2OD1{N{WuPFQhdk1? NF64WI1USU6JRWK=
NCI-H810 M{Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KO2pKSzVyPUK3PE4{OSCwTR?= MXXTRW5ITVJ?
LB771-HNC Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HvcGlEPTB;Mki1Mlg1KG6P M3P3bHNCVkeHUh?=
LCLC-103H M2D5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ6NT65PUBvVQ>? NEjCdJlUSU6JRWK=
EFO-21 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ6Nz62PEBvVQ>? M3zUfHNCVkeHUh?=
CAL-72 NXXKR|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD1{OUOuNVkhdk1? MXnTRW5ITVJ?
SCC-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ7Mz6yNkBvVQ>? NEm3bGlUSU6JRWK=
COLO-829 M37G[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLMemFIUUN3ME2yPVYvPSCwTR?= NULXc3J5W0GQR1XS
U-87-MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnnTHV[UUN3ME2zNFAvPzNibl2= MV3TRW5ITVJ?
MZ7-mel Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHsfXdwUUN3ME2zNlMvPzZibl2= NVjZ[4MxW0GQR1XS
NCI-H1770 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjCe|VXUUN3ME2zNlYvPzRibl2= NFLlXXNUSU6JRWK=
ChaGo-K-1 M1r0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmy[|M4UUN3ME2zNlgvOSCwTR?= MnnhV2FPT0WU
SiHa M1voPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C0SWlEPTB;M{K5MlI1KG6P M1mwSnNCVkeHUh?=
NCI-SNU-5 M{\sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PsXmlEPTB;M{O2Mlc4KG6P NHT6dJRUSU6JRWK=
DJM-1 M{nPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXMTWM2OD1|NECuN|Mhdk1? M{PqTHNCVkeHUh?=
OE19 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvjTWM2OD1|NECuOVMhdk1? Mkf4V2FPT0WU
NCI-H1651 NHnZTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN2ND6xPEBvVQ>? NULYTFZwW0GQR1XS
COLO-792 NEjr[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K3SmlEPTB;M{W0MlQzKG6P MlW1V2FPT0WU
ACHN NYnyUVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrycYg5UUN3ME2zOVYvPzFibl2= M2DEO3NCVkeHUh?=
TH-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN5OT65OUBvVQ>? NHjRcoFUSU6JRWK=
HT-1376 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LDRmlEPTB;M{i0Mlg5KG6P MWTTRW5ITVJ?
RH-18 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGxTWM2OD1|OUSuO|Qhdk1? MofVV2FPT0WU
NB6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[zS2JKSzVyPUO5Ok43PiCwTR?= NFX5WWZUSU6JRWK=
COLO-320-HSR NY\tbJpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvOXo9iUUN3ME20NFMvOzdibl2= M1O3UHNCVkeHUh?=
UACC-893 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LiTGlEPTB;NEC2MlQ4KG6P MXHTRW5ITVJ?
DSH1 M2WxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLzTWM2OD12ME[uPVEhdk1? NGLRVGpUSU6JRWK=
TE-10 M3XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD12MEeuNFEhdk1? NUK1NVFYW0GQR1XS
HCC70 M2LGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRyOT6yNUBvVQ>? MX7TRW5ITVJ?
TGBC11TKB M1T5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3bYllUUN3ME20NVAvOzNibl2= MkTFV2FPT0WU
NCI-H727 M4HXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrKTWM2OD12MUKuNVEhdk1? MYfTRW5ITVJ?
ALL-PO NYTPXHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDFVWFKSzVyPUSxOU43QSCwTR?= M1vEW3NCVkeHUh?=
ABC-1 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHOV|RSUUN3ME20NlAvPDVibl2= NH\YdoZUSU6JRWK=
NCI-H69 NXzFbG46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjEN3ZKSzVyPUSyOk44PiCwTR?= MVrTRW5ITVJ?
GP5d M4fx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR|ND60NUBvVQ>? NX2zd|g2W0GQR1XS
UMC-11 M2PmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR3OD6zOkBvVQ>? M4GzWHNCVkeHUh?=
RMG-I NF:xdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILv[YlKSzVyPUS2O{42PiCwTR?= NYXEbWNMW0GQR1XS
YAPC M1jWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOS5ExUUN3ME20PVAvPiCwTR?= NIK0NIhUSU6JRWK=
LS-1034 NX75SnA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jBOWlEPTB;NEmxMlA3KG6P NIrUVVJUSU6JRWK=
RCM-1 NFLjVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULNVYd7UUN3ME20PVYvPjhibl2= MmDaV2FPT0WU
HCC1954 NYjEdJZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVzMj61JI5O MVfTRW5ITVJ?
SK-MEL-24 NVvwUVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLpR5BKSzVyPUWxOk42OSCwTR?= MkfUV2FPT0WU
NB12 M4PCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXhTI5UUUN3ME21NlgvPDJibl2= NUf2Z|BXW0GQR1XS
SW756 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT2Um1QUUN3ME21OVQvQTZibl2= MoTiV2FPT0WU
HCC1187 NGDub21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTV5NT64N{BvVQ>? NEK5UGxUSU6JRWK=
NCI-H2342 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTV7MD6zPUBvVQ>? MUPTRW5ITVJ?
NCI-H2291 NVrLfo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fBcmlEPTB;NUm4MlMyKG6P M{nOVXNCVkeHUh?=
OVCAR-3 NGHhdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm5[HpKSzVyPUW5PE46PiCwTR?= MUnTRW5ITVJ?
MHH-NB-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe5VGxKSzVyPU[yPU4xOSCwTR?= MYrTRW5ITVJ?
SAS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\s[Y1KSzVyPU[1Nk43PyCwTR?= MYDTRW5ITVJ?
COLO-824 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPHOZNLUUN3ME22PFkvOzdibl2= NXriXGhLW0GQR1XS
HCC1395 NGPxTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnub5BNUUN3ME22PVgvPSCwTR?= Mn\1V2FPT0WU
COLO-668 NHv3OnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nKO2lEPTB;N{C2MlEhdk1? MXHTRW5ITVJ?
NCI-H226 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXLTWM2OD15MEeuPEBvVQ>? NYq4UVBVW0GQR1XS
NB17 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\q[lU4UUN3ME23NlEvPzVibl2= M4\DOHNCVkeHUh?=
SW1463 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xid2lEPTB;N{O5MlE6KG6P MXHTRW5ITVJ?
TGW MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGyXHhKSzVyPUe2NE4yPSCwTR?= M3PUVHNCVkeHUh?=
NCI-H526 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTh{Mz61N{BvVQ>? NVXTeW4{W0GQR1XS
COR-L88 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X6eGlEPTB;OES4MlEzKG6P MU\TRW5ITVJ?
NCI-H441 NWL2fXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHlTWM2OD16OUWuNlIhdk1? MorHV2FPT0WU
NCI-H630 NH74RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLZTWM2OD17MUKuPVYhdk1? Ml33V2FPT0WU
Mo-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33OPGlEPTB;OUS3Mlg5KG6P M4\RTnNCVkeHUh?=
JAR M3f2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGyWINKSzVyPUm1Ok4zPCCwTR?= NFHMPJBUSU6JRWK=
NCI-H1838 NIDUd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX4XpFKSzVyPUGuNFI{QDhizszN NVrqdlFyW0GQR1XS
DoTc2-4510 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHKepd[UUN3ME2xMlA4Ozd4IN88US=> NVvXRnRYW0GQR1XS
MKN28 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMEmwNlQh|ryP NEXVbY5USU6JRWK=
HuP-T3 NX;LeZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK5d5M6UUN3ME2xMlEyQTB3IN88US=> MYrTRW5ITVJ?
TE-9 NUfWbplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPjWZIyUUN3ME2xMlEzQTd|IN88US=> NXzKZmROW0GQR1XS
NY NXm2bXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7jV2FKUUN3ME2xMlE3Pzl{IN88US=> NXHhcFFOW0GQR1XS
HT55 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33uTmlEPTB;MT6zNVM1PCEQvF2= MonEV2FPT0WU
SW837 NXvzcmxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4S4FKSzVyPUGuN|I6PzhizszN M2ryenNCVkeHUh?=
NCI-H2029 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXmTWM2OD1zLkSxO|kyKM7:TR?= MmHaV2FPT0WU
IST-SL1 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELzXJdKSzVyPUGuOFQzPCEQvF2= NGX3NnJUSU6JRWK=
COLO-741 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DX[GlEPTB;MT60PVc4OSEQvF2= MXzTRW5ITVJ?
LU-65 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES2UYhKSzVyPUGuOlIzPDlizszN MXfTRW5ITVJ?
NCI-H1304 NF3SNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ETWM2OD1zLk[1OFk5KM7:TR?= MoPyV2FPT0WU
KARPAS-299 M3G5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;5TWM2OD1zLke5OFc6KM7:TR?= M2fJfXNCVkeHUh?=
NCI-H358 NIL2UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXZTWM2OD1zLkm1OVA{KM7:TR?= MluzV2FPT0WU
OAW-28 NWHzeJQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzBWItuUUN3ME2yMlA3QTF7IN88US=> MYLTRW5ITVJ?
C8166 NVfFd21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme2TWM2OD1{Lk[zN|kzKM7:TR?= MU\TRW5ITVJ?
COLO-678 M4W4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7OTWM2OD1{LkizO|Y5KM7:TR?= MWXTRW5ITVJ?
SK-N-DZ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwOE[zPFEh|ryP NV\QV3JSW0GQR1XS
NCI-H82 NEfEbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwOUCzOlkh|ryP NI\0[odUSU6JRWK=
JVM-2 M1;5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf1[lBOUUN3ME2zMlA{OTh6IN88US=> MXXTRW5ITVJ?
SW1116 NEfFZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDZc3RKSzVyPUOuNFU1OTFizszN MnTxV2FPT0WU
MDA-MB-453 M2Pzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vHfWlEPTB;Mz6xNFQ{QSEQvF2= NWLnVmZjW0GQR1XS
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LpbGlEPTB;Mz6xPVk4KM7:TR?= MX\TRW5ITVJ?
SHP-77 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHFTWM2OD1|LkWyPEDPxE1? NF\4S5hUSU6JRWK=
Capan-2 M3:1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWexXmoxUUN3ME20MlMzPThzIN88US=> NFHxZ4FUSU6JRWK=
SW948 NGD1NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wTWM2OD12Lke0O|c6KM7:TR?= MVnTRW5ITVJ?
HDLM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXTWM2OD13LkC3O|I2KM7:TR?= M2jr[nNCVkeHUh?=
LAN-6 M2HmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZwMkG0PVUh|ryP NUDXeFNoW0GQR1XS
LU-135 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi1cmdKSzVyPU[uOFMxPzdizszN NYnyWGdvW0GQR1XS
T84 M133[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Sx[GlEPTB;Nj65PFY1KM7:TR?= MlPtV2FPT0WU
CAPAN-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX60N3U1UUN3ME23MlYzOjN|IN88US=> MULTRW5ITVJ?
SW1417 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzwTWM2OD15LkmxO|MyKM7:TR?= M{K2[HNCVkeHUh?=
BALL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPuOG9{UUN3ME24MlUxPDB7IN88US=> MV;TRW5ITVJ?
HT-29 NHfkWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\tcoJKSzVyPUmuNFc2QTlizszN MVHTRW5ITVJ?
C3A M{jQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3nTWM2OD17Lki4N|k1KM7:TR?= Mn3PV2FPT0WU
NCI-H1993 M{PTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFyLkWwPFEh|ryP M2PWc3NCVkeHUh?=
SK-MEL-1 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFzLk[yPFkh|ryP MVnTRW5ITVJ?
DU-145 NG\FbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD2TWM2OD1zND61NFUzKM7:TR?= MXnTRW5ITVJ?
KP-N-YN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ENGlEPTB;MUSuOVExOyEQvF2= MYPTRW5ITVJ?
CCRF-CEM MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HGfWlEPTB;MUSuO|gxQSEQvF2= NVztZY9{W0GQR1XS
ZR-75-30 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT5[3NKSzVyPUG2MlM{ODNizszN M3PSXXNCVkeHUh?=
A673 M2TzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJyLkW1NFch|ryP M4XIO3NCVkeHUh?=
K-562 NGH1OYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Se2lEPTB;MkiuOFE5OyEQvF2= MnfnV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. [1]

Protocol

Kinase Assay:

[1]
+ Expand

In vitro Protein Kinase, PI3K, and mTOR Assays:

PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research:

[2]
+ Expand
  • Cell lines: HCT116, DLD-1 and SW480 cells
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 103 cells/well, DLD-1: 5.5 × 103 cells/well, SW480: 4.5 × 103 cells/well, DLD-1 PIK3CA mutant: 7 × 103 cells/well, and DLD-1 PIK3CA wild-type: 9 × 103 cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Female Harlan athymic nude mice
  • Formulation: NMP/polyethylene glycol 300 (10/90, v/v)
  • Dosages: 45 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMF 18 mg/mL warmed (38.33 mM)
DMSO 0.01 mg/mL (0.02 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
NMP+polyethylene glycol 300 (10+90, v+v)
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 469.55
Formula

C30H23N5O
CAS No. 915019-65-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03373903 Active not recruiting Respiratory Tract Infections Restorbio Inc. November 15 2017 Phase 2
NCT01856101 Terminated Carcinoma Transitional Cell Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Novartis February 2013 Phase 2
NCT01717898 Terminated Castrate-resistant Prostate Cancer Charles Ryan|Novartis Pharmaceuticals|University of California San Francisco January 31 2013 Phase 1|Phase 2
NCT01658436 Completed Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis November 2012 Phase 2
NCT01628913 Terminated Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis October 2012 Phase 2
NCT01690871 Withdrawn Malignant PEComa (Perivascular Epithelioid Cell Tumors) Novartis Pharmaceuticals|Novartis September 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    With difficulties in dissolving BEZ235, How can I improve its solubility?

  • Answer:

    For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317 New

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • Buparlisib (BKM120, NVP-BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy Dactolisib (BEZ235, NVP-BEZ235) | Dactolisib (BEZ235, NVP-BEZ235) supplier | purchase Dactolisib (BEZ235, NVP-BEZ235) | Dactolisib (BEZ235, NVP-BEZ235) cost | Dactolisib (BEZ235, NVP-BEZ235) manufacturer | order Dactolisib (BEZ235, NVP-BEZ235) | Dactolisib (BEZ235, NVP-BEZ235) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID